Potential of thrombolytic therapy in the early period of ST-elevation myocardial infarction. Expert consensus

The article presents an overview of the largest randomized and observational studies on the efficacy and safety of primary percutaneous coronary intervention (PCI) and pharmacoinvasive strategy for ST-elevation myocardial infarction (STEMI).

The management of STEMI patients is one of the most discussed and pressing issues in modern cardiology, since timely myocardial revascularization significantly affects both patient mortality and long-term prognosis. It has been established that the key factor in choosing reperfusion therapy for STEMI should be the time from the onset of symptoms. Due to the fact that it is not possible to ensure the time before opening the infarct-related artery up to 120 minutes in all patients referred for primary PCI in real-world practice, prehospital thrombolysis can significantly improve their prognosis. Pharmacoinvasive approach with prehospital bolus administration of thrombolytic agents should currently be considered as a priority strategy in STEMI if primary PCI within 120 min after diagnosis is not possible. A pharmacoinvasive approach with prehospital bolus administration of thrombolytic agents should be considered as an alternative to primary PCI in the first 3 hours from the STEMI onset in cases where primary PCI cannot be performed within 1 hour after diagnosis.

1. Rangel FOD. Reperfusion Strategies in Acute Myocardial Infarction: State of the Art. Int J Cardiovasc Sci. 2021;35(1):113-22. doi:10.36660/ijcs.20200226.

2. Kumar A, Vora K, Bhatt DL et al. The Canadian Cardiovascular Society Classification of acute atherothrombotic myocardial infarction provides a novel staging scheme based on tissue injury severity. Eur Heart J. 2024;45(12):976-9. doi:10.1093/eurheartj/ehad821.

3. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733-42. doi:10.1056/NEJMoa025142.

4. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809-14. doi:10.1161/01.CIR.0000091088.63921.8C.

5. Le May MR, Wells GA, Labinaz M, et al. Combined Angioplasty and Pharmacological Intervention Versus Thrombolysis Alone in Acute Myocardial Infarction (CAPITAL-AMI Study). Jour nal of the American College of Cardiology. 2005;46(3):417-24. doi:10.1016/j.jacc.2005.04.042.

6. Fernandez-Avilés F, Alonso JJ, Castro-Beiras A, et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet. 2004;364(9439):1045-53. doi:10.1016/S0140-6736(04)17059-1.

7. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20. doi:10.1016/s0140-6736(03)12113-7.

8. Bøhmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol. 2010;55(2):102-10. doi:10.1016/j.jacc.2009.08.007.

9. Fernández-Avilés F, Alonso JJ, Peña G, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. European Heart Journal. 2007;28(8):949-60. doi:10.1093/eurheartj/ehl461.

10. Pu J, Ding S, Ge H, et al. Efficacy and safety of a pharmacoinvasive strategy with half-dose alteplase versus primary angioplasty in ST segment-elevation myocardial infarction: EARLY-MYO trial (early routine catheterization after alteplase fibrinolysis versus primary PCI in acute ST segment-elevation myocardial infarction). Circulation. 2017;136:1462-73. doi:10.1161/CIRCULATIONAHA.117.030582.

11. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367(9510):569-78. doi:10.1016/S0140-6736(06)68147-6.

12. Paul W, Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) Study. Eur Heart J. 2006;27:1530-8. doi:10.1093/eurheartj/ehl088.

13. Fazel R, Joseph TI, Sankardas MA, et al. Comparison of Reperfusion Strategies for ST-Segment-Elevation Myocardial Infarction: A Multivariate Network Meta-analysis. J Am Heart Assoc. 2020;9(12): e015186. doi:10.1161/JAHA.119.015186.

14. Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368:1379-87. doi:10.1056/NEJMoa1301092.

15. Van de Werf F, Ristić AD, Averkov OV, et al. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial. Circulation. 2023;148(9):753-64. doi:10.1161/CIRCULATIONAHA.123.064521.

16. Larson DM, Duval S, Sharkey SW, et al. Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. Eur Heart J. 2012;33(10):1232-40. doi:10.1093/eurheartj/ehr403.

17. Li K, Zhang B, Zheng B, et al. Reperfusion Strategy of ST-Elevation Myocardial Infarction: A Meta-Analysis of Primary Percutaneous Coronary Intervention and Pharmaco-Invasive Therapy. Front Cardiovasc Med. 2022;9:813325. doi:10.3389/fcvm.2022.813325.

18. Roule V, Ardouin P, Blanchart K, et al. Prehospital fibrinolysis versus primary percutaneous coronary intervention in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized controlled trials. Critical Care. 2016;20:359. doi:10.1186/s13054-016-1530-z.

19. Fordyce CB, Cairns JA, Singer J, et al. Evolution and Impact of a Regional Reperfusion System for ST-Elevation Myocardial Infarction. Can J Cardiol. 2016;32(10):1222-30. doi:10.1016/j.cjca.2015.11.026.

20. Arbel Y, Ko DT, Yan AT, et al. Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Can J Cardiol. 2018;34(6):736-43. doi:10.1016/j.cjca.2018.02.005.

21. Rao SV, O’Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation. Circulation. 2025;151(13): e771-e862. doi:10.1161/CIR.0000000000001309.

22. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023; 44(38):3720-826. doi:10.1093/eurheartj/ehad191.

23. Averkov OV, Harutyunyan GK, Duplyakov DV, et al. 2024 Clinical practice guidelines for Acute myocardial infarction with ST segment elevation electrocardiogram. Russian Journal of Cardiology. 2025;30(3):6306. (In Russ.) doi:10.15829/1560-4071-2025-6306. EDN IVJCUK.

24. Boytsov SA, Shakhnovich RM, Tereschenko SN, et al. Features of the reperfusion therapy for ST-Segment elevation myocardial infarction according to the Russian Registry of Acute Myocardial Infarction — REGION-IM. Kardiologiia. 2024;64(2):3-17. (In Russ.) doi:10.18087/cardio.2024.2.n2601.

25. Jortveit J, Pripp AH, Halvorsen S, et al. Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway. Eur Heart J Cardiovasc Pharmacother. 2022;8(5):442-51. doi:10.1093/ehjcvp/pvab041.

26. Jamal J, Idris H, Faour A, et al. Late outcomes of ST-elevation myocardial infarction treated by pharmaco-invasive or primary percutaneous coronary intervention. Eur Heart J. 2023;44(6):516-28. doi:10.1093/eurheartj/ehac661.

27. Oleynik BA, Starodubov VI, Evdakov VA, Abzalilova LR. Association of mortality rates and availability of emergency and specialized, including high-tech, medical services for acute coronary syndrome in the Russian Federation. Russian Journal of Cardiology. 2023;28(9):5514. (In Russ.) doi:10.15829/1560-4071-2023-5514.

28. Boersma E. Does time matter? A pooled analysis of randomized clinical trials comparing primarypercutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006;27:779-88. doi:10.1093/eurheartj/ehi810.

29. Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation. 2009;119:1293-303. doi:10.1161/CIRCULATIONAHA.108.796383.

30. Welsh RC, Goldstein P, Adgey J, et al. Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. Eur J Emerg Med. 2004;11:134-40.

31. Bainey KR, Armstrong PW, Zheng Y, et al. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice. Circulation: Cardiovascular Interventions. 2019;12: e008059. doi:10.1161/CIRCINTERVENTIONS.119.008059.

32. Bainey KR, Ferguson C, Ibrahim QI, et al. Impact of reperfusion strategy on aborted myocardial infarction: insights from a large Canadian ST-elevation myocardial infarction clinical registry. Can J Cardiol. 2014;30:1570-5. doi:10.1016/j.cjca.2014.08.021.

33. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomized study. Lancet. 2002;360:825-9. doi:10.1016/S0140-6736(02)09963-4.

34. Westerhout CM, Bonnefoy E, Welsh RC, et al. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J. 2011;161(2):283-90. doi:10.1016/j.ahj.2010.10.033.

35. Danchin N, Coste P, Ferrieres J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: data from the French registry in acute ST-elevation myocardial infarction (FASTMI). Circulation. 2008;118:268-76. doi:10.1161/CIRCULATIONAHA.107.762765.

36. Mannsverk J, Steigen T, Wang H, et al. Trends in clinical outcomes and survival following prehospital thrombolytic therapy given by ambulance clinicians for ST-elevation myocardial infarction in rural sub-arctic Norway. Eur Heart J. Acute Cardiovasc Care. 2019;8(1):8-14. doi:10.1177/2048872617748550.

37. Ting HH, Rihal CS, Gersh BJ, et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI protocol. Circulation. 2007;116:729-36. doi:10.1161/CIRCULATIONAHA.107.699934.

38. Kalla K, Christ G, Karnik R, et al., for the Vienna STEMI Registry Group. Implementation of guidelines improves the standard of care: the Viennese Registry on reperfusion strategies in ST-elevation myocardial infarction (Vienna STEMI Registry). Circulation. 2006;113:2398-405. doi:10.1161/CIRCULATIONAHA.105.586198.

39. Wong GC, Welsford M, Ainsworth C, et al. 2019 Canadian Cardiovascular Society/ Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion. Canadian Journal of Cardiology. 2019;35(2):107-32. doi:10.1016/j.cjca.2018.11.031.